A notable advancement in diabetes treatment is emerging with the approval of tirzepatide in a 45mg form. This innovative version builds upon the existing success of tirzepatide, a dual GIP and GLP-1 agonist, and https://bookmarksaifi.com/story21400985/significant-approach-tirzepatide-dose-for-glucose-control